Description
Herpes zoster is an acute viral infection caused by reactivation of varicella-zoster virus (VZV). LZV, a live, attenuated vaccine for zoster has been available in Canada for many years. A new subunit recombinant zoster vaccine (RZV) named Shingrix was approved in Canada in October 2017. This zoster vaccine immunogenicity review was done to have a comprehensive understanding of the immunogenicity of both live and subunit vaccines.
Resources
| Name | Format | Description | Link |
|---|---|---|---|
| Literature Review on the Immunogenicity of Herpes Zoster Vaccines | HTML | Open resource | |
| Literature Review on the Immunogenicity of Herpes Zoster Vaccines | HTML | Open resource |